David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies. In this Q&A conversation, the Eye Care Network ...

The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.

Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates in Dallas, moderated a recent Modern Retina Case-Based Roundtable on diagnosing and treating patients with macular telangiectasia type 2 ...

A recent Modern Retina Case-Based Roundtable highlighted the management of geographic atrophy (GA) and how young physicians and fellows can shape patient care, according to Samuel A. Minaker, MD, who ...

Panelists discuss how pivotal RVO trial data for aflibercept 8 mg show strong durability and visual outcomes while raising questions about long-term disease chronicity and vascular remodeling under ...

The novel system converts light into electrical signals to stimulate retinal cells. In the retinas of patients with GA, the photoreceptors, which are adversely affected by the disease, fail to convert ...

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability, with treatment selection ultimately guided by patient characteristics and ...

The company did not receive the necessary stockholder votes to approve the merger agreement with Alcon at the Special Meeting of Stockholders held on January 6, 2026. STAAR Surgical has announced that ...

Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and patient comfort influence confidence in adopting the higher-dose formulation.

Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using multimodal approaches, and avoiding premature treatment switching. In this ...

For Jordan M. Graff, MD, FACS, early adoption is about reigniting the thrill of discovery and navigating the rewards, risks, and realities of translating innovation into practice. In this installment, ...

The FDA noted in the letter that it is unable to approve the application for ONS-5010/LYTENAVA (bevacizumab-vikg) in its current form for the treatment of wet AMD. Outlook Therapeutics, Inc. reported ...